🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Agendia announced we will be presenting new data on our early-stage breast cancer genomic tests, MammaPrint® and Blueprint®, and their ability to inform treatment selection decisions at SABCS! To learn more, visit: bit.ly/4i4nAYI #SABCS2024

BTS at Cortical Labs #MWC25

Attention Belgium HCPs: Join us for a live webinar with Dr. William Audeh & Dr. Caroline Drukker! Learn how MammaPrint & BluePrint help HCPs identify genomically High-Risk ESBC patients needing neoadjuvant & adjuvant treatment.   Register now! qrco.de/bfmKkh

Join Agendia’s Dinner Symposium during ASBRS held on Friday May 2nd from 7:30–9pm PST at the Bellagio (rooms 3, 4, & 7). Dr. Jaime Alberty, and Dr. Beth DuPree will discuss MammaPrint and BluePrint for neoadjuvant treatment and surgical planning. Register now via the link!

📢 ¡Nuestro hospital Hosp. Germans Trias pone en marcha la primera unidad de endoscopia respiratoria robótica 🤖de España! 🫁 Enhorabuena al Dr. Antoni Rosell y todo su equipo por este nuevo hito que consolida a nuestro centro como auténtico hub de innovación.

- Consistent with ISPY2 findings, BP HER2 showed higher pCR rates than BP Luminal Suggests BP improves stratification and personalization. - Potentially reduces NHT for BP Luminal tumors with estimated poor response. Read more at the link. shorturl.at/ZvLiI

Discover how the latest findings from the FLEX study can help you identify which HR+/HER2- early-stage breast cancer patients may respond to neoadjuvant chemotherapy using MammaPrint and BluePrint. Read the study by Dr. O'Shaughnessy to learn more! #Agendia #BreastCancer

Join Agendia’s educational Dinner Symposium at ASBRS on Friday, May 2nd, from 7:30–9 PM PST at the Bellagio. Dr. Jaime Alberty and Dr. Beth DuPree will speak about MammaPrint and BluePrint for neoadjuvant treatment and surgical planning.

Navigating #biomarker testing in early-stage #breastcancer can be overwhelming. To learn more about the tests available and how to communicate results with patients, attend this webinar from Living Beyond Breast Cancer on April 10. Learn more and register: bit.ly/3QRVe7q

Our founder, Laura J. Van't Veer, PhD received the William L. McGuire Memorial Lecture Award at SABCS 2024 for her pioneering work in risk stratification, subtyping & early breast cancer treatment with MammaPrint and I-SPY 2. Learn more in this interview with Dr. Kate Lathrop.

youtube.com/watch?v=TWwsLN… #Agendia #IlluminatingTumorBiology #BreastCancer #SABCS2024

Scientists Uncover Hidden Protein Driving Autoimmune Attacks nanoappsmedical.com/scientists-unc… c.c. Amanda Scott Heinz V. Hoenen 🌻 Frank Boehm🌻

HER2+ early-stage #breastcancer response to neoadjuvant targeted therapy by #Blueprint gene-expression based functional subtyping test. Agendia #illuminatingtumorbiology #precisiononcology

Of >105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome🧵 Nature Medicine

¿Conoces los 5 perfiles moleculares de MammaPrint + BluePrint en el cáncer de mama ER+/HER2-? 👉 Acompáñanos en esta serie de 5 webinars con el Dr. William Audeh, director médico de Agendia, para profundizar en cada clasificación genómica: agendia.com/webinar-series…

Starting #breastcancer session at OM3d

We're honored to be named the 2025 MedTech Breakthrough Award Winner for Best Overall Genomic Company! 🏆 At Agendia, we empower women with early-stage breast cancer and their care teams with personalized, biology-based insights that guide truly individualized care. 💙 #Agendia

📢📝NEW Data presented at #ESMOBreast25: The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis. View the Poster Here: ow.ly/QfVY50VTbkp #breastcancer #genomics #illuminatingtumorbiology @adam brufsky

Sign up to learn how Agendia genomic test #Mammaprint and #Blueprint assess on #breast #cancer risk of recurrence. It's a 30 min webinar series, don't miss it out! #precisiononcology #illuminatingtumorbiology

👋🏼 ¿Nos ayudas a mejorar la atención a pacientes con #cáncerdemama localizado HR+/HER2-? Desde GEICAM - Cáncer de mama, en colaboración con otras sociedades científicas, asociaciones de pacientes y Novartis España, estamos impulsando un estudio nacional que busca conocer en profundidad las